Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Voyage Medical Inc.

This article was originally published in Start Up

Executive Summary

One of the challenges with catheter ablation for cardiac arrhythmias is that while electrophysiologists are delivering energy through a catheter to the heart, they have very limited feedback as to what is occurring at the point of therapy. They rely on fluoroscopy or ultrasound to monitor catheter positioning, but those technologies do not provide adequate resolution. Clinicians may soon be able to visualize the target sites of the heart, transforming electrophysiology and potentially all endocardial treatments. The IRIS catheter from Voyage Medical is both a visualization and therapeutic platform to treat arrhythmias. The fiber-optic visualization system is integrated into the catheter and it provides real-time feedback on what is happening during the ablation procedure.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel